Loading
companiesCompany
Panbela Therapeutics
Panbela Therapeutics is a Minnesota biotech whose drug ivospemin starves pancreatic cancer of polyamines, molecules the tumour needs to grow, and is being tested with gemcitabine and nab-paclitaxel in first-line treatment.
Also called: Sun BioPharmaNASDAQ:PBLA
Overview
Panbela Therapeutics, formerly Sun BioPharma, develops polyamine-targeting therapies. Ivospemin (SBP-101) is a polyamine analogue that is taken up preferentially by pancreatic acinar and cancer cells and disrupts polyamine metabolism. The phase 2/3 ASPIRE trial tested ivospemin with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. Through its acquisition of Cancer Prevention Pharmaceuticals it also holds eflornithine-based programmes for familial adenomatous polyposis.
Headquarters
Waconia, Minnesota, US
Scorecard
All companies#450of 1244 companies, score 7
- phase 3 +3
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:PBLA
Stage
Public
Website
Phase 3small molecule
Ivospemin is an experimental small-molecule drug from Panbela Therapeutics in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.
drugs
Phase 3small molecule